Supernus Pharma (SUPN) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Supernus Announces Third Quarter 2017 Financial Results
November 6, 2017 5:00 PM ESTThird quarter net product sales were $78.1 million, a 40% increase over 2016. Third quarter operating income was $22.3 million, a 13% increase over 2016.Initiated Phase III clinical trials for SPN-812.Initiated Oxtellar XR investigator-sponsored trial in bipolar disorder.Increased full year 2017 net product sales guidance range to $290 million to $295 million, from $280 million to $290 million, and operating income guidance range to $85 million to $90 million, from $82 million to $87 million.
ROCKVILLE, Md., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the... More
